All In Biotech

Drug Trial Radar · NCT04109222

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

Collection of Serum Samples From Children 6 Months to < 9 Years of Age Who Received Fluzone® Quadrivalent and Adults ≥ 65 Years of Age Who Received Fluzone® High-Dose, Influenza Vaccines, 2019-2020 Formulations

Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

90

Actual

Start

Sep 30, 2019

Primary completion

Dec 10, 2019

Study completion Dec 10, 2019

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 83 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study was to provide sera (collected from participants before vaccination \[Blood Sample 1\] and after final vaccination \[Blood Sample 2\]) to the Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines.

Conditions

  • Influenza

Interventions

  • Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulationBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • Fluzone High-Dose vaccine, 2019-2020 formulationBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Aged 6 Months to < 9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2Time frame: Visit 1 (Day 0; pre-vaccination) and 28 days post-final vaccination at Visit 2/Visit 3
  2. Number of Participants Aged >= 65 Years Who Provided Serum Samples for Analysis: Group 3Time frame: Visit 1 (Day 0; pre-vaccination) and 21 days post-vaccination (Visit 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 8400002

    Bardstown, Kentucky

  • Investigational Site Number 8400001

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.